Pfizer Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2012. For the quarter, the company reported net income attributable to the company of $6,315 million or $0.85 per diluted share on revenue of $15,068 million against net income attributable to the company of $1,439 million or $0.19 per diluted share on revenue of $16,141 million for the same period a year ago. Income from continuing operations was $1,490 million or $0.20 per diluted share against $1,413 million or $0.18 per diluted share for the same period a year ago. Income from continuing operations before provision for taxes on income was $2,170 million against $2,155 million for the same period a year ago. Adjusted income was $3,512 million or $0.47 per diluted share compared to $3,784 million or $0.49 per diluted share for the same period a year ago.

For the full year, the company reported net income attributable to the company of $14,570 million or $1.94 per diluted share on revenue of $58,986 million against net income attributable to the company of $10,009 million or $1.27 per diluted share on revenue of $65,259 million for the same period a year ago. Income from continuing operations was $9,518 million or $1.26 per diluted share against $8,395 million or $1.06 per diluted share for the same period a year ago. Income from continuing operations before provision for taxes on income was $12,080 million against $12,304 million for the same period a year ago. Adjusted income was $16,476 million or $2.19 per diluted share compared to $17,839 million or $2.27 per diluted share for the same period a year ago.

The company provided earnings guidance for the year 2013. The company expects a range for revenues of $56.2 to $58.2 billion and for adjusted diluted EPS of $2.20 to $2.30. Adjusted SI&A expenses to be between $15.6 billion and $16.6 billion. Adjusted R&D expenses to be between $6.5 billion and $7.0 billion. Effective tax rate on adjusted income to be approximately 28.0%. Reported diluted EPS to be between $2.20 to $2.30.

The company reported for the fourth quarter, certain asset impairment charges of $366 million compared to $277 million for the same period last year.